» Authors » Jun Horiguchi

Jun Horiguchi

Explore the profile of Jun Horiguchi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 266
Citations 3052
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Yashima H, Araki T, Ishikawa Y, Ohshima S, Nagano D, Obayashi K, et al.
Mol Clin Oncol . 2024 Dec; 22(2):12. PMID: 39649026
Docetaxel is metabolized by cytochrome P450 3A4 (CYP3A4), and is transported by organic anion transporting peptides (OATPs) and ABCB1, and its blood concentration is known to affect the risk of...
2.
Ikeda T, Honda C, Kurozumi S, Yokobori T, Katayama A, Masuda K, et al.
Anticancer Res . 2024 Oct; 44(11):4877-4883. PMID: 39477305
Background/aim: Family with sequence similarity 83 member G (FAM83G) plays an important role in cancer aggressiveness and patients' prognosis across various types of cancer. However, the association of FAM83G protein...
3.
Sekine C, Horiguchi J
Int J Clin Oncol . 2024 Sep; 29(11):1641-1647. PMID: 39297908
Breast imaging has several modalities, each unique in terms of its imaging position, evaluation index, and imaging method. Breast diagnosis is made by combining a large number of past imaging...
4.
Horiguchi J, Wake R, Murotani K, Seno H, Miyaoka T, Inoue K
PCN Rep . 2024 Jun; 2(4):e155. PMID: 38868736
Aim: We conducted a 12-week double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of yokukansan in patients with schizophrenia. Methods: Patients with schizophrenia resistant to antipsychotics whose Positive...
5.
Sugawara-Komatsu K, Fujii T, Kurozumi S, Ishikawa H, Katayama A, Handa T, et al.
Anticancer Res . 2024 May; 44(6):2689-2698. PMID: 38821605
Background/aim: There are two main subtypes of mucinous carcinoma (MC) based on the quantification of the mucinous component: the pure variant (pMC) and the mixed variant (mMC). pMC has been...
6.
Katayama A, Aoki Y, Watanabe Y, Horiguchi J, Rakha E, Oyama T
Int J Clin Oncol . 2024 Apr; 29(11):1648-1668. PMID: 38619651
Breast cancer is the most prevalent cancer among women, and its diagnosis requires the accurate identification and classification of histological features for effective patient management. Artificial intelligence, particularly through deep...
7.
Narusawa E, Kurozumi S, Katayama A, Koibuchi Y, Ogawa A, Takata D, et al.
Med Mol Morphol . 2024 Apr; 57(3):177-184. PMID: 38619618
In some cases of human epidermal growth factor 2 (HER2)-negative breast cancer, including triple-negative breast cancer, HER2 expression is sporadically and strongly upregulated, a condition known as HER2 heterogeneity. We...
8.
Honda C, Kurozumi S, Fujii T, Pourquier D, Khellaf L, Boissiere F, et al.
Theranostics . 2024 Mar; 14(5):1873-1885. PMID: 38505604
The tumor microenvironment (TME) and its multifaceted interactions with cancer cells are major targets for cancer treatment. Single-cell technologies have brought major insights into the TME, but the resulting complexity...
9.
Kurozumi S, Seki N, Narusawa E, Honda C, Tokuda S, Nakazawa Y, et al.
Int J Mol Sci . 2024 Jan; 25(1). PMID: 38203206
This study aimed to identify microRNAs associated with histological grade using comprehensive microRNA analysis data obtained by next-generation sequencing from early-stage invasive breast cancer. RNA-seq data from normal breast and...
10.
JiueLan K, Sekine C, Kurozumi S, Matsuoka R, Komuta M, Shiomi T, et al.
Radiol Case Rep . 2023 Sep; 18(11):3828-3830. PMID: 37670913
Fibrocystic breast disease is the most common benign condition and is important for differentiating breast cancer. We present the case of a 27-year-old female patient with pleomorphic calcifications and segmental...